Evidence map›Paper›PMID 36000937›Full record

ArticlePediatric dermatology2022

Toxic epidermal necrolysis after first dose of Pfizer-BioNTech (BNT162b2) vaccination with pharmacogenomic testing.

Nunthana Siripipattanamongkol, Sirawich Rattanasak, Chanya Taiyaitieng, Yanapha Inthajak, Nitchamon Kuawatcharawong, Chonlaphat Sukasem, Therdpong Tempark

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Cutaneous Adverse Events After COVID-19 Vaccination.Clinical, cosmetic and investigational dermatology · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Nunthana SiripipattanamongkolDepartments of Pediatrics, Chiangrai Prachanukroh Hospital, Chiangrai, Thailand.
Sirawich RattanasakDepartments of Pediatrics, Chiangrai Prachanukroh Hospital, Chiangrai, Thailand.
Chanya TaiyaitiengDepartments of Medicine, Chiangrai Prachanukroh Hospital, Chiangrai, Thailand.
Yanapha InthajakDepartments of Ophthalmology, Chiangrai Prachanukroh Hospital, Chiangrai, Thailand.
Nitchamon KuawatcharawongDepartments of Surgery, Chiangrai Prachanukroh Hospital, Chiangrai, Thailand.
Chonlaphat SukasemDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.ORCID https://orcid.org/0000-0003-0033-5321
Therdpong TemparkDepartment of Pediatrics, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.ORCID https://orcid.org/0000-0001-5645-2135
ChiangRai Prachanukroh Hospital · THChulalongkorn University · THUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxic epidermal necrolysis (TEN) is a rare and acute life-threatening condition and one of the severe cutaneous adverse drug reactions. There are limited data on TEN from the COVID-19 vaccine regarding its pathogenesis, treatment, and prognosis, particularly in children. We report a case of COVID-19 vaccine-induced TEN and the patient's human leukocyte antigen pharmacogenomic profile.

Indexed as

COVID-19COVID-19 VaccinesStevens-Johnson SyndromeBNT162 VaccineChildHumansPharmacogenomic TestingVaccinationBNT162 VaccineCOVID-19 VaccinesCOVID-19 vaccinepharmacogenomicstoxic epidermal necrolysis

Identifiers

PMID36000937
PMCPMC9538630
OpenAlexW4292997400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.